X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
OBI-992 is a novel antibody drug conjugate (ADC) cancer therapy targeting TROP2. It is being evaluated for the treatment of non-small cell lung cancer, small cell lung cancer & gastric cancer.
Lead Product(s): OBI-992
Therapeutic Area: Oncology Product Name: OBI-992
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: OBI Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
BSI-045B is a high-affinity, humanized monoclonal antibody, targeting thymic stromal lymphopoietin (TSLP), a cytokine that is implicated in the pathogenesis of atopic dermatitis, asthma and other eosinophilic and Th2 immune-related diseases.
Lead Product(s): BSI-045B,Dupilumab
Therapeutic Area: Dermatology Product Name: BSI-045B
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
Details:
CDX-585 is a dual targeting PD-1/ILT4 bispecific antibody from Celldex’s bispecific antibody platform, being developed for the treatment of solid tumors either as monotherapy or in combination with other oncologic treatments.
Lead Product(s): CDX-585
Therapeutic Area: Oncology Product Name: CDX-585
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Celldex Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
BSI-045B is a high-affinity, humanized monoclonal antibody, targeting thymic stromal lymphopoietin (TSLP), a cytokine that is implicated in the pathogenesis of atopic dermatitis, asthma and other eosinophilic and Th2 immune-related diseases.
Lead Product(s): BSI-045B
Therapeutic Area: Dermatology Product Name: BSI-045B
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
Biosion will leverage its proprietary SynTracer® high-throughput endocytosis platform to generate highly selective antibodies to targets allocated by each company and ImmunoGen will provide their proprietary linker-payload technology to create novel Antibody-Drug Conjugates.
Lead Product(s): Antibody-drug Conjugates
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Immunogen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 13, 2022
Details:
The license agreement enables OBI Pharma to conduct further preclinical and clinical development, registration, and commercialization of BSI04702 as an Antibody Drug Conjugate and other derivative products.
Lead Product(s): BSI04702
Therapeutic Area: Oncology Product Name: BSI04702
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: OBI Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 13, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
